Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotorasib and Panitumumab in KRAS p.G12C Mutated Metastatic Colorectal Cancer
NCT05198934Phase 3Completed
- Sponsor
- Amgen
- Start
- Apr 2022
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial of sotorasib in colorectal cancer (CRC) (3 arms), sponsored by Amgen. Primary endpoint: Progression-free Survival at 6.23 months. Started Apr 2022; status: completed.
02
Drugs
sotorasib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05198934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05198934.